Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2022 16:01 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results

Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on...
August 02, 2022 08:00 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
July 18, 2022 07:05 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)

DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
June 24, 2022 07:30 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Announces Sale of Hospital Products

Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 millionGoing forward, Eton’s commercial portfolio will exclusively focus on products...
May 12, 2022 16:02 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
May 03, 2022 16:02 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
April 11, 2022 16:01 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
April 11, 2022 07:30 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection

DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
March 16, 2022 16:02 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results

Fourth Quarter 2021 Revenue of $6.1 millionFourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq:...
March 14, 2022 07:00 ET | Source: Eton Pharmaceuticals

Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)

DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine...